FDA Approves First Oral Treatment for Adult Dermatomyositis

The FDA has approved Lisraya (brepocitinib) tablets, marking the first oral drug specifically for treating dermatomyositis in adults. This rare autoimmune disease causes chronic inflammation, muscle weakness, and distinct skin rashes. The approval addresses a significant unmet medical need, providing a targeted oral therapy for patients who previously relied on treatments for other conditions, potentially improving patient outcomes.